Administration of the tablet formulation of olaparib in patients with ovarian cancer: practical guidance and expectations
KN Moore, MJ Birrer - The Oncologist, 2018 - academic.oup.com
Olaparib is a poly (ADP‐ribose) polymerase enzyme inhibitor that is approved for use in
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
[PDF][PDF] Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations
KN Moore, MJ Birrer - The Oncologist, 2018 - Wiley Online Library
Olaparib is a poly (ADP‐ribose) polymerase enzyme inhibitor that is approved for use in
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations
KN Moore, MJ Birrer - The oncologist, 2018 - pubmed.ncbi.nlm.nih.gov
Olaparib is a poly (ADP-ribose) polymerase enzyme inhibitor that is approved for use in
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
KN Moore, MJ Birrer - The Oncologist, 2018 - europepmc.org
Olaparib is a poly (ADP‐ribose) polymerase enzyme inhibitor that is approved for use in
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
[HTML][HTML] Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations
KN Moore, MJ Birrer - The Oncologist, 2018 - ncbi.nlm.nih.gov
Olaparib is a poly (ADP‐ribose) polymerase enzyme inhibitor that is approved for use in
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
KN Moore, MJ Birrer - Oncologist, 2018 - search.ebscohost.com
Abstract: Olaparib is a poly (ADP‐ribose) polymerase enzyme inhibitor that is approved for
use in patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who …
use in patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who …
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
KN Moore, MJ Birrer - The Oncologist, 2018 - europepmc.org
Olaparib is a poly (ADP‐ribose) polymerase enzyme inhibitor that is approved for use in
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …
patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have …